Promising 12-month follow-up data that shows the world's first leadless pacemaker is demonstrating overall device performance comparable to conventional pacemakers has been reported by Vivek Reddy, MD, Director of Arrhythmia Services for The Mount Sinai Hospital.
Dr. Reddy presented the one-year LEADLESS study data findings during his late-breaking clinical trial presentation on May 9 at Heart Rhythm 2014, the Heart Rhythm Society's 35th Annual Scientific Sessions in San Francisco, CA.
Tips to Prevent Heart Attacks
Heart Attack occurs when the flow of oxygenated blood to heart muscles is hindered or stopped due to built-up of plaques in coronary arteries. Heart Attack is the No.1 killer among Indians.
Advertisement
The LEADLESS study's long-term follow-up has evaluated 32 patients with a slowed heartbeat, bradycardia, who successfully received St. Jude Medical's Nanostim™ leadless pacemaker at two hospitals in Prague and one in Amsterdam. The findings, which assessed device performance and patient outcomes through 12-months of follow-up, show pacing thresholds (0.43 volts) and sensing (10.32 mV) of the leadless pacemaker device are equivalent to those in traditional pacemakers. In addition, there was no experience of infections or failure to sense, pace, or communicate with the pacemaker.
"This is the first time we've seen one-year follow-up data for this innovative, wireless cardiac pacing technology and our results show the leadless pacemaker is comparable to traditional pacemakers," says Dr. Vivek Reddy, Director of Arrhythmia Services at The Mount Sinai Hospital who is the study's co-investigator and Chairman of its Steering Committee. "Our latest findings further support the promising performance and safety of this minimally-invasive, non-surgical pacing device. More long-term follow-up of these LEADLESS study patients will further our understanding of the potential advantages, benefits, and complication risks of leadless pacemaker technology, along with additional ongoing, larger trials."
![Congestive Heart Failure]( "Congestive Heart Failure")
Congestive heart failure (CHF) is a condition in which the heart fails to work adequately as a pump that can deliver oxygen rich blood to the body.
In February, Dr. Reddy was the first to implant the leadless pacemaker in the United States at The Mount Sinai Hospital launching the multicenter clinical trial LEADLESS II which aims to further test the leadless pacemaker more widely for safety and efficacy in 670 patients at 50 centers across the US and Canada.
The miniature-sized, leadless cardiac pacemaker is placed directly inside a patient's heart without surgery during a catheter-guided procedure through the groin via the femoral vein. The device, resembling a tiny, metal silver tube and smaller than a triple-A battery, is only a few centimeters in length, making it less than ten percent the size of a traditional pacemaker. It works by closely monitoring the heart's electrical rhythms and if the heart beat is too slow it provides electrical stimulation therapy to regulate it. More than 4 million patients globally have a pacemaker, and 700,000 new patients receive one each year.
In comparison to a conventional pacemaker, the new-age leadless pacemaker eliminates the need for a surgical pocket and no visible pacemaker device under a patient's chest skin, no incision scar on the chest, no connector wires or leads, and no restrictions on a patient's daily activities. The device's benefits may also allow for less patient discomfort, infections, and device complications and dysfunction.
Source: Eurekalert
Congestive Heart Failure
Congestive heart failure (CHF) is a condition in which the heart fails to work adequately as a pump that can deliver oxygen rich blood to the body.
Advertisement
In February, Dr. Reddy was the first to implant the leadless pacemaker in the United States at The Mount Sinai Hospital launching the multicenter clinical trial LEADLESS II which aims to further test the leadless pacemaker more widely for safety and efficacy in 670 patients at 50 centers across the US and Canada.
The miniature-sized, leadless cardiac pacemaker is placed directly inside a patient's heart without surgery during a catheter-guided procedure through the groin via the femoral vein. The device, resembling a tiny, metal silver tube and smaller than a triple-A battery, is only a few centimeters in length, making it less than ten percent the size of a traditional pacemaker. It works by closely monitoring the heart's electrical rhythms and if the heart beat is too slow it provides electrical stimulation therapy to regulate it. More than 4 million patients globally have a pacemaker, and 700,000 new patients receive one each year.
In comparison to a conventional pacemaker, the new-age leadless pacemaker eliminates the need for a surgical pocket and no visible pacemaker device under a patient's chest skin, no incision scar on the chest, no connector wires or leads, and no restrictions on a patient's daily activities. The device's benefits may also allow for less patient discomfort, infections, and device complications and dysfunction.
Source: Eurekalert
Congenital Heart Disease
Heart diseases that are present at birth are called " Congenital heart diseases".
Advertisement
 Diet from Crete for Healthy HeartMediterranean diets, special attention has been given to the traditional Greek Cretan diet. It emphasises the consumption of olive oil, whole grains, pulses, wild greens, herbs and fruits. | Advertisement
|
Advertisement
Recommended Readings
Latest Heart Disease News
Atrial fibrillation (irregular heart rhythm) can be accurately diagnosed with Verily Study Watch, the FDA-approved wrist-worn gadget.
According to health experts, an increased risk of heart attack, stroke, and blood clots is associated with higher hemoglobin levels.
Early cardiac evaluation reverses atherosclerosis caused by cardiac risk factors like high BP and high cholesterol in young adults.
PM2.5 increases during winter inversions are associated with higher heart attack risk, stated study.
The study underscores the significance of broader genetic testing for familial hypercholesterolemia, a genetic disorder that causes high bad cholesterol levels.